Amgen Highlights Cardiometabolic Advances at ADA 86th Scientific Sessions

Amgen Inc. (NASDAQ: AMGN) announced new clinical findings at the American Diabetes Association’s 86th Scientific Sessions, emphasizing the company’s continued focus on cardiometabolic conditions. The presentation underscored the therapeutic potential of Amgen’s lipid‑lowering and glucose‑modulating products, and highlighted the importance of adherence in achieving real‑world effectiveness.

VESALIUS‑CV: A Phase‑Three Evaluation of Repatha® in High‑Risk Diabetic Patients

  • Study Design VESALIUS‑CV was a randomized, double‑blind, placebo‑controlled phase‑three trial involving 6,142 patients with type 2 diabetes who were at high cardiovascular risk. Participants received standard lipid‑lowering therapy (statin ± ezetimibe) plus either the PCSK9 inhibitor Repatha® (alirocumab) or placebo, in addition to their usual glucose‑lowering regimen.

  • Primary Endpoint The composite of major adverse cardiovascular events (MACE) – non‑fatal myocardial infarction, non‑fatal stroke, and cardiovascular death – was the primary endpoint.

  • Key Results

  • Repatha reduced MACE by 23 % compared with placebo (hazard ratio = 0.77, 95 % CI = 0.66–0.90; p < 0.001).

  • The benefit was consistent across subgroups, including patients concurrently taking SGLT‑2 inhibitors (HR = 0.75) or GLP‑1 receptor agonists (HR = 0.78).

  • LDL‑cholesterol levels fell by an average of 51 % versus 6 % in the placebo arm, demonstrating robust lipid lowering.

  • Clinical Implications The trial confirms that aggressive LDL‑lowering with a PCSK9 inhibitor confers additional cardiovascular protection in diabetic patients who remain at high residual risk despite statin therapy. The consistency across glucose‑lowering backgrounds suggests additive benefit independent of glycemic control.

Real‑World Evidence on GLP‑1 Therapy Persistence

Amgen presented observational data from a large claims‑based cohort (n > 45,000) examining persistence of GLP‑1 receptor agonists in routine practice:

  • Discontinuation Rates

  • Within 12 months of initiation, 41 % of patients discontinued therapy.

  • Median duration of use was 8.1 months for once‑weekly formulations and 6.3 months for daily preparations.

  • Factors Influencing Persistence

  • Higher baseline BMI, older age, and presence of comorbid cardiovascular disease were associated with greater adherence.

  • Adverse events, injection burden, and cost were common reasons for early discontinuation.

  • Impact on Outcomes Patients who persisted beyond 12 months achieved greater reductions in HbA1c (Δ 0.9 %) and weight (Δ 4.2 kg) compared with those who discontinued early, underscoring the therapeutic value of sustained use.

  • Strategic Recommendations Amgen highlighted the need for real‑time adherence monitoring, patient education, and combination therapies that reduce injection frequency (e.g., dual‑acting agents) to improve long‑term outcomes.

Commitment to Obesity and Residual Cardiovascular Risk

Amgen reiterated its portfolio strategy focusing on agents that target residual risk factors beyond LDL‑cholesterol:

  • Obesity‑Focused Pipeline

  • Development of a novel satiety‑modulating peptide (AMG‑xxxx) aimed at reducing body mass index and improving metabolic parameters in obese patients with or without diabetes.

  • Preclinical models demonstrate a 22 % reduction in adipose tissue mass and a 15 % improvement in insulin sensitivity after 12 weeks of administration.

  • Cardiovascular Risk Reduction

  • A phase‑two trial of AMG‑xxxx in patients with established cardiovascular disease is underway, measuring endpoints such as carotid intima‑media thickness and arterial stiffness.

  • Amgen is collaborating with regulatory agencies to streamline the approval pathway, leveraging the FDA’s Regulatory Science initiatives that support the use of surrogate biomarkers.

Regulatory and Commercial Outlook

  • Regulatory Pathway

  • The VESALIUS‑CV data will support a supplemental New Drug Application (sNDA) for Repatha® in the indication of “high‑risk diabetic patients with residual cardiovascular risk.”

  • Amgen anticipates an FDA review within 12–14 months, contingent on the availability of comprehensive safety data.

  • Market Dynamics

  • The global PCSK9 inhibitor market is projected to exceed $4 billion by 2027, with diabetic patients representing a growing segment.

  • Improved adherence strategies for GLP‑1 therapies could unlock substantial value, given the current underutilization in real‑world settings.

Conclusion

Amgen’s presentation at the ADA Scientific Sessions reinforced its role as a leader in integrated lipid and glucose management. The VESALIUS‑CV results provide robust evidence for the cardiovascular benefit of Repatha® in high‑risk diabetic populations, while real‑world data on GLP‑1 therapy adherence highlight an opportunity for improved patient outcomes. Continued investment in obesity‑centric agents and residual risk reduction therapies positions Amgen to address unmet needs at the intersection of metabolic disease and cardiovascular health.